Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia.

Duangporn Jamsai1, Faten Zaibak, Jim Vadolas

  • 1Cell and Gene Therapy Research Group, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, VIC 3052, Australia. duangporn.jamsai@med.monash.edu.au

Genomics
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice.

American journal of hematology·2026
Same author

Neutrophil extracellular traps induced by activated platelets as a cause of neutrophil-platelet aggregation in β-thalassaemia/haemoglobin E patients.

British journal of haematology·2026
Same author

CCND3 Suppression Ameliorates β-Thalassaemia in a Murine Disease Model: A Potential Therapeutic Strategy.

Cells·2026
Same author

An Australian standard of care for Niemann-Pick disease type C.

Internal medicine journal·2026
Same author

Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: Results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial.

Metabolism: clinical and experimental·2026
Same author

Effect of long-term sepiapterin treatment on dietary phenylalanine tolerance in patients with phenylketonuria: Interim results from the phase 3 APHENITY Extension Study.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

A new mouse model for Hemoglobin E (HbE) was created using humanized transgenics. This model mimics HbE/beta-thalassemia patient conditions, aiding in disease study and therapy development.

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • Hemoglobin E (HbE) results from a specific beta-globin gene mutation (G to A at codon 26), causing unstable hemoglobin and mild anemia.
  • HbE is prevalent in Southeast Asia, with carrier frequencies up to 80%.
  • Co-inheritance of HbE with beta-thalassemia leads to severe disease.

Purpose of the Study:

  • To create and evaluate humanized transgenic mice carrying the human beta-globin locus with the beta(E) mutation.
  • To establish an in vivo model for studying HbE pathophysiology and testing new treatments.

Main Methods:

  • Generation of humanized transgenic mice with the beta(E) mutation.
  • Analysis of hematological parameters in heterozygous and homozygous knockout mice carrying the transgene.

Related Experiment Videos

  • Assessment of transgene copy number effects on the phenotype.

    • Main Results:

    • The human beta(E) locus transgene partially corrected hematological issues in heterozygous mice.
    • The transgene rescued embryonic lethality in homozygous mice, with outcomes dependent on copy number.
    • The developed mouse model exhibits hematological abnormalities mirroring those in HbE/beta-thalassemia patients.

    Conclusions:

    • Humanized transgenic mice carrying the beta(E) mutation serve as a valuable in vivo model for HbE/beta-thalassemia.
    • This model facilitates further pathophysiological research and the preclinical evaluation of therapeutic strategies for HbE-related disorders.